Home News General Long-time supporter of GALVmed, Professor Andy Peters appointed Interim CEO

Professor Andy Peters has been appointed as GALVmed’s Interim Chief Executive Officer.  Andy Peters has been involved with GALVmed almost since the organisation’s beginning as a member of the initial Technical Advisory Committee and latterly as GALVmed’s Chief Scientific Advisor. Andy has produced various technical reports for the organisation, prepared the registration dossier for the East Coast fever vaccine (ECF-ITM) and managed the registration process in Kenya and Tanzania.

Andy acted as interim Head of Research and Development pending Dr Baptiste Dungu’s appointment in November 2008. Recently, Andy’s work has been focused on the regulatory documentation for Newcastle disease vaccine in Africa as well as providing advisory input and supporting GALVmed staff on other projects.

Professor Andy Peters commented:

I believe passionately in GALVmed and am honoured and proud to have been appointed to this position.  Working with GALVmed in various capacities over the past six years I have seen tremendous growth as well as challenges for the organisation.  In this interim role, I am committed to providing continuity as well as supporting and strengthening GALVmed’s leadership.

GALVmed’s Deputy Chairperson, Professor Julie Fitzpatrick said:

Good progress is being made on the appointment of a permanent CEO and I am delighted that Andy Peters has taken on this interim role.  Having worked across GALVmed projects and departments for some years, Andy has a deep understanding of this organisation, one to which his expertise and people-skills have already contributed greatly.  Andy brings a wealth of experience, including technical, commercial and leadership abilities and well understands the challenges and opportunities that exist in this new phase of delivery at scale.  

Relevant career highlights: 

Andy has recently been running a consultancy company ARPEXAS Ltd, providing support in new product development to the animal health industry and academia. He was also Vice President, Animal Health, at AspenBio Pharma Inc, Denver, Colorado, USA from 2009-2011. Andy has spent his career in various positions in industry and academia, most recently as head of EU vaccine R&D for Zoetis (1998-2005) and Professor of Animal Health, Royal Veterinary College, University of London (1993-1998).

Education: He is a veterinarian with PhD and DSc degrees in animal science and currently holds a visiting professorial appointment at the University of Nottingham.

Key publications: He has published approximately 155 papers in the scientific and professional literature and is a regular contributor to scientific and industry meetings.

Interests: His interest is in translating high quality research into veterinary products and increasing the availability of veterinary medicines to poor livestock farmers.